Fleury S.A. (FLRY3) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.076x

Based on the latest financial reports, Fleury S.A. (FLRY3) has a cash flow conversion efficiency ratio of 0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$418.29 Million ≈ $82.08 Million USD) by net assets (R$5.52 Billion ≈ $1.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Fleury S.A. for the company's overall valuation and market capitalisation.

Fleury S.A. - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Fleury S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Fleury S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fleury S.A. ranked by their cash flow conversion efficiency. Explore FLRY3 cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Zhejiang Yonghe Refrigerant Co Ltd
SHG:605020
0.028x
WaFd, Inc.
NASDAQ:WAFD
0.023x
Skshu Paint Co Ltd
SHG:603737
0.221x
Arcplus Group PLC
SHG:600629
0.035x
Zhejiang Orient Holdings Co Ltd
SHG:600120
0.049x
Jenoptik AG
F:JEN
0.034x
Dongguan Yiheda Automation Co. Ltd.
SHE:301029
N/A
Angang Steel Co Ltd Class A
SHE:000898
0.036x

Annual Cash Flow Conversion Efficiency for Fleury S.A. (2006–2025)

The table below shows the annual cash flow conversion efficiency of Fleury S.A. from 2006 to 2025. View Fleury S.A. stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 R$5.10 Billion
≈ $999.98 Million
R$1.57 Billion
≈ $308.32 Million
0.308x -14.16%
2024-12-31 R$5.37 Billion
≈ $1.05 Billion
R$1.93 Billion
≈ $378.80 Million
0.359x +27.54%
2023-12-31 R$5.11 Billion
≈ $1.00 Billion
R$1.44 Billion
≈ $282.42 Million
0.282x -22.94%
2022-12-31 R$2.70 Billion
≈ $530.00 Million
R$987.13 Million
≈ $193.69 Million
0.365x -33.47%
2021-12-31 R$1.85 Billion
≈ $363.88 Million
R$1.02 Billion
≈ $199.88 Million
0.549x +48.61%
2020-12-31 R$1.75 Billion
≈ $343.55 Million
R$647.14 Million
≈ $126.98 Million
0.370x -11.22%
2019-12-31 R$1.76 Billion
≈ $345.14 Million
R$732.32 Million
≈ $143.69 Million
0.416x +3.86%
2018-12-31 R$1.75 Billion
≈ $343.37 Million
R$701.49 Million
≈ $137.64 Million
0.401x +29.17%
2017-12-31 R$1.71 Billion
≈ $334.85 Million
R$529.61 Million
≈ $103.92 Million
0.310x -11.67%
2016-12-31 R$1.54 Billion
≈ $301.34 Million
R$539.57 Million
≈ $105.87 Million
0.351x +57.78%
2015-12-31 R$1.66 Billion
≈ $324.83 Million
R$368.63 Million
≈ $72.33 Million
0.223x +22.60%
2014-12-31 R$1.57 Billion
≈ $308.64 Million
R$285.71 Million
≈ $56.06 Million
0.182x +46.38%
2013-12-31 R$1.69 Billion
≈ $331.42 Million
R$209.59 Million
≈ $41.12 Million
0.124x +26.71%
2012-12-31 R$1.71 Billion
≈ $334.73 Million
R$167.05 Million
≈ $32.78 Million
0.098x +9.49%
2011-12-31 R$1.63 Billion
≈ $320.20 Million
R$145.96 Million
≈ $28.64 Million
0.089x -19.86%
2010-12-31 R$1.01 Billion
≈ $198.53 Million
R$112.92 Million
≈ $22.16 Million
0.112x +289.62%
2009-12-31 R$838.97 Million
≈ $164.62 Million
R$24.03 Million
≈ $4.72 Million
0.029x -93.99%
2008-12-31 R$151.84 Million
≈ $29.79 Million
R$72.40 Million
≈ $14.21 Million
0.477x -39.20%
2007-12-31 R$101.35 Million
≈ $19.89 Million
R$79.48 Million
≈ $15.60 Million
0.784x +16.44%
2006-12-31 R$105.91 Million
≈ $20.78 Million
R$71.33 Million
≈ $14.00 Million
0.673x --

About Fleury S.A.

SA:FLRY3 Brazil Diagnostics & Research
Market Cap
$2.32 Billion
R$11.82 Billion BRL
Market Cap Rank
#5665 Global
#65 in Brazil
Share Price
R$21.74
Change (1 day)
-1.18%
52-Week Range
R$14.20 - R$22.11
All Time High
R$26.18
About

Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medi… Read more